Table 1. Clinical data of patients in the malignant or benign SPNs groups.
| Clinical data | Malignant SPNs (n=184) | Benign SPNs (n=39) |
|---|---|---|
| CTCs level (FU/3 mL) | 10.48±3.49 | 6.38±0.53 |
| CTCs (malignant/benign) | 164/20 | 3/36 |
| Age (years) | ||
| ≤60 | 94 | 21 |
| >60 | 90 | 18 |
| Sex | ||
| Male | 79 | 11 |
| Female | 105 | 28 |
| Pathological subtypes | ||
| Squamous cell carcinoma | 34 | – |
| Adenocarcinoma | 147 | – |
| Adenosquamous cell carcinoma | 3 | – |
| Differentiation level | ||
| G1 | 99 | – |
| G2 | 67 | – |
| G3 | 18 | – |
| Location of SPNs | ||
| Left lobe | 91 | 19 |
| Right lobe | 93 | 20 |
| Location of SPNs | ||
| Upper lobe | 121 | 20 |
| Middle lobe | 8 | 4 |
| Lower lobe | 55 | 15 |
| Largest diameter of SPNs (cm) | ||
| ≤1 | 66 | 23 |
| >1 | 118 | 16 |
| T stage | ||
| T1 | 126 | – |
| T2 | 42 | – |
| T3 | 16 | – |
| N stage | ||
| N0 | 153 | – |
| N1 | 25 | – |
| N2 | 6 | – |
| TNM stage | ||
| Stage I | 137 | – |
| Stage II | 41 | – |
| Stage III | 6 | – |
| Smoking history | ||
| N/A | 160 | 30 |
| I/A | 24 | 9 |
| Tumor biomarkers (positive/negative) | ||
| CEA | 51/133 | 8/31 |
| CA125 | 55/129 | 6/33 |
| CA724 | 53/131 | 8/31 |
| CYFRA21-1 | 56/128 | 7/32 |
| NSE | 76/108 | 5/34 |
| CEA + CA125 + CA724 + CYFRA21-1 + NSE | 109/75 | 9/30 |
SPN, solitary pulmonary nodule; CTCs, circulating tumor cell; N/A, not available; I/A, is available; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA724, carbohydrate antigen 724; CYFRA21-1, cytokeratin fragment 21-1; NSE, neuron-specific enolase.